tropifexor
Jump to navigation
Jump to search
Indications
- investigational treatment of primary biliary cholangitis[1]
Dosage
- 20, 60 or 90 ug QD
Mechanism of action
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 Walker M Novel Non-Bile FXR Agonist Promising in PBC Patients Phase II trial interim analysis found dose-dependent response, good safety profile. MedPage Today. April 15, 2018 https://www.medpagetoday.com/meetingcoverage/easl/72355
Schramm C, et al Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis European Association for the Study of the Liver (EASL) 2018. Abstract LBO-007.